Long-Term Outcomes of Surgery for Thymic Carcinoma: Experience of 25 Cases at a Single Institution

 

 Buy Article Permissions and Reprints All articles of this category

Abstract

Background Thymic carcinoma, a relatively rare entity, often presents as locally advanced disease, and sometimes as distant metastatic disease. The treatment strategy, long-term surgical outcomes and clinical prognostic factors have yet to be fully elucidated.

Methods Clinical charts of 25 patients who underwent surgery for thymic carcinoma at our institution from 1991 to 2014 were retrospectively reviewed.

Results The Masaoka stage was stage I in three patients (12%), II in eight (32%), III in four (16%), IVa in four (16%), and IVb in six (24%). Histologic subtypes were squamous cell carcinoma in 12 patients, well-differentiated neuroendocrine carcinoma in 5, undifferentiated carcinoma in 3, adenocarcinoma in 1, and others in 4. Three patients had paraneoplastic syndrome including myasthenia gravis, multiple endocrine neoplasia type 1 (MEN1), and Cushing syndrome. Neoadjuvant chemotherapy was administered to five patients (20%). Complete resection was achieved in 17 patients (68%). There were no perioperative deaths. Twelve patients received postoperative therapy. The 5- and 10-year overall survival rates were 76.2 and 63.5%, respectively. The 5- and 10-year survival rates of patients with Masaoka stage I–III were 88.9 and 74.1%, respectively, whereas the 5-year survival rate of stage IV was 50.0%. The 5- and 10-year survival rates of 17 patients who underwent complete resection were 88.9 and 71.1%, respectively. Of the 17 patients with complete resection, 3 patients experienced recurrence including lung and supraclavicular lymph node.

Conclusion Even for this highly malignant disease, surgery could contribute to favorable long-term outcomes in the setting of multimodality therapy.

Note

This study was presented at the 4th International Thymic Malignancy Interest Group Annual Meeting, Bethesda, Maryland, United States, September 6–7, 2013.[22]

• References

• 1 Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg 2013; 95 (1) 299-303
  CrossrefPubMedGoogle Scholar
• 2 Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg 2010; 89 (3) 912-917
  CrossrefPubMedGoogle Scholar
• 3 Chalabreysse L, Etienne-Mastroianni B, Adeleine P, Cordier JF, Greenland T, Thivolet-Bejui F. Thymic carcinoma: a clinicopathological and immunohistological study of 19 cases. Histopathology 2004; 44 (4) 367-374
  CrossrefPubMedGoogle Scholar
• 4 Venuta F, Anile M, Diso D , et al. Thymoma and thymic carcinoma. Eur J Cardiothorac Surg 2010; 37 (1) 13-25
  CrossrefPubMedGoogle Scholar
• 5 Okuma Y, Horio H, Hosomi Y , et al. The potency of curative-intent treatment for advanced thymic carcinoma. Lung Cancer 2014; 84 (2) 175-181
  CrossrefPubMedGoogle Scholar
• 6 Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003; 76 (3) 878-884 , discussion 884–885
  CrossrefPubMedGoogle Scholar
• 7 Korst RJ, Bezjak A, Blackmon S , et al. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg 2014; 147 (1) 36-44 , 46.e1
  CrossrefPubMedGoogle Scholar
• 8 Venuta F, Rendina EA, Longo F , et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 2003; 76 (6) 1866-1872 , discussion 1872
  CrossrefPubMedGoogle Scholar
• 9 Lucchi M, Ambrogi MC, Duranti L , et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005; 79 (6) 1840-1844
  CrossrefPubMedGoogle Scholar
• 10 Marx A, Strobel P, Zettl A , et al. Pathology and Genetics of Tumours of the Lung, Thymus and Heart. Lyon, France: IARC Press; 2004: 152-153
  Google Scholar
• 11 Filosso PL, Guerrera F, Rendina AE , et al. Outcome of surgically resected thymic carcinoma: a multicenter experience. Lung Cancer 2014; 83 (2) 205-210
  CrossrefPubMedGoogle Scholar
• 12 Weissferdt A, Moran CA. Thymic carcinoma, part 1: a clinicopathologic and immunohistochemical study of 65 cases. Am J Clin Pathol 2012; 138 (1) 103-114
  CrossrefPubMedGoogle Scholar
• 13 Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48 (11) 2485-2492
  CrossrefPubMedGoogle Scholar
• 14 Ruffini E, Van Raemdonck D, Detterbeck F, Rocco G, Thomas P, Venuta F. European Society of Thoracic Surgeons Thymic Questionnaire Working Group. Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol 2011; 6 (3) 614-623
  CrossrefPubMedGoogle Scholar
• 15 Ruffini E, Detterbeck F, Van Raemdonck D , et al; European Association of Thoracic Surgeons (ESTS) Thymic Working Group. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg 2014; 46 (3) 361-368
  CrossrefPubMedGoogle Scholar
• 16 Okuma Y, Hosomi Y, Takagi Y , et al. Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 2013; 80 (1) 75-80
  CrossrefPubMedGoogle Scholar
• 17 Agatsuma T, Koizumi T, Kanda S , et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 2011; 6 (12) 2130-2134
  CrossrefPubMedGoogle Scholar
• 18 Evans TL, Lynch TJ. Role of chemotherapy in the management of advanced thymic tumors. Semin Thorac Cardiovasc Surg 2005; 17 (1) 41-50
  CrossrefPubMedGoogle Scholar
• 19 Ogawa K, Toita T, Uno T , et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002; 94 (12) 3115-3119
  CrossrefPubMedGoogle Scholar
• 20 Tseng YL, Wang ST, Wu MH, Lin MY, Lai WW, Cheng FF. Thymic carcinoma: involvement of great vessels indicates poor prognosis. Ann Thorac Surg 2003; 76 (4) 1041-1045
  CrossrefPubMedGoogle Scholar
• 21 Yano M, Sasaki H, Yokoyama T , et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008; 3 (3) 265-269
  CrossrefPubMedGoogle Scholar
• 22 Tagawa T, Nakajima T, Iwata T , et al. Favorable outcome of aggressive surgery for thymic carcinoma: an experience of 23 cases at a single institution. ITMIG 2013 4th International Thymic Malignancy Interest Group Annual Meeting. Abstract book; 2013; 46–47
  PubMedGoogle Scholar